Effective for dates of service on and after July 1, 2015, pharmacy claims for the following physician-administered injectable drugs administered on an outpatient basis will be reimbursable under Michigan Medicaid and the Healthy Michigan Plan:

- Mental health and substance abuse injectable drugs, as listed on the Prepaid Inpatient Health Plan (PIHP)/Community Mental Health Services Program (CMHSP) Physician Injectable Drug Coverage Database, found at [www.michigan.gov/medicaidproviders](http://www.michigan.gov/medicaidproviders) >> Billing and Reimbursement >> Provider Specific Information >> Mental Health/Substance Abuse >> PIHP/CMH Injectable Drugs
- 17 Alpha Hydroxyprogesterone Caproate (17P and Makena)

This change will allow pharmacy providers to be reimbursed for these injectable drugs for administration in an outpatient setting using a rate based on the National Drug Code (NDC). The rates for drug product reimbursement are outlined in the Michigan Medicaid State Plan. Professional or institutional claims for physician-administered injectable drugs will continue to be covered. Pharmacies and prescribing practitioners must ensure that claims are not duplicated. This policy applies to Fee-for-Service claims.

**For Practitioners**

Practitioners must submit the claim for the injectable drug as a professional or institutional claim if the practitioner purchases the drug directly through a pharmacy, distributor or wholesaler. If the practitioner uses a pharmacy to acquire the drug for administration, the pharmacy must submit the claim as a pharmacy claim. There is no copayment responsibility to the beneficiary for the injectable drug; however, there may be a copayment for the office visit to administer the drug.

**For Pharmacy Providers**

As a reminder, pharmacy providers may not dispense a physician-administered injectable drug directly to the beneficiary – to ensure the content and integrity of the drug administered to the beneficiary the drug must be delivered from the pharmacy directly to the physician for administration. The method of delivery of the injectable drug to the physician should be agreed upon by the pharmacy and physician. The refrigeration, stabilization, and other storage and handling requirements of the drug must be met during delivery and at all points of the transaction. The costs associated with the delivery of the injectable drug to the physician are not reimbursable by the Michigan Department of Health and Human Services (MDHHS).
The injectable drug must be administered to the beneficiary within 14 days of the arrival of the drug to the physician’s office. For multi-dose vials, the first dose must be administered to the beneficiary within 14 days of the arrival of the drug to the physician’s office. For the safety of our program beneficiaries and to minimize waste, procedures should be established to return unused medications to the pharmacy when appropriate. Restocking returned product should be compliant with Michigan Board of Pharmacy guidelines.

This policy does not apply to coverage of pharmacy claims for vaccines.

**Manual Maintenance**

Retain this bulletin until the information is incorporated into the Medicaid Provider Manual.

**Questions**

Any questions regarding this bulletin should be directed to Provider Inquiry, Department of Health and Human Services, P.O. Box 30731, Lansing, Michigan 48909-8231, or e-mail at ProviderSupport@michigan.gov. When you submit an e-mail be sure to include your name, affiliation, and phone number so you may be contacted if necessary. Providers may phone toll-free 1-800-292-2550.

**Approved**

Stephen Fitton, Director
Medical Services Administration